Cargando…

The Microbiome and Protein Carbamylation: Potential Targets for Protein-Restricted Diets Supplemented with Ketoanalogues in Predialysis Chronic Kidney Disease

In chronic kidney disease (CKD), metabolic derangements resulting from the interplay between decreasing renal excretory capacity and impaired gut function contribute to accelerating disease progression and enhancing the risk of complications. To protect residual kidney function and improve quality o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faerber, Valentin, Kuhn, Katharina S., Garneata, Liliana, Kalantar-Zadeh, Kamyar, Kalim, Sahir, Raj, Dominic S., Westphal, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459041/ https://www.ncbi.nlm.nih.gov/pubmed/37630693 http://dx.doi.org/10.3390/nu15163503

Ejemplares similares

Safety of Low-Protein Diets and Ketoanalogue Supplementation in CKD
por: Ikizler, T. Alp
Publicado: (2018)

Protein carbamylation is associated with heart failure and mortality in diabetic patients with end stage renal disease
por: Drechsler, Christiane, et al.
Publicado: (2015)

Narrative Review of Incremental Hemodialysis
por: Murea, Mariana, et al.
Publicado: (2019)

Urea and protein carbamylation in ESRD: Surrogate markers or partners in crime?
por: Velasquez, Manuel T, et al.
Publicado: (2015)

Predialysis Potassium Variability and Postdialysis Mortality in Patients With Advanced CKD
por: Dashputre, Ankur A., et al.
Publicado: (2021)

Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies
por: Nakabo, Shuichiro, et al.
Publicado: (2017)

Protein Carbamylation and Cardiovascular Disease
por: Verbrugge, Frederik H., et al.
Publicado: (2015)

The Impact of Carbamylation and Anemia on HbA(1c)’s Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease
por: Tang, Mengyao, et al.
Publicado: (2023)

Endogenous Carbamylation of Renal Medullary Proteins
por: Claxton, J'Neka S., et al.
Publicado: (2013)

Adherence to ketoacids/essential amino acids-supplemented low protein diets and new indications for patients with chronic kidney disease
por: Fouque, Denis, et al.
Publicado: (2016)

Proteasome-dependent degradation of intracellular carbamylated proteins
por: Desmons, Aurore, et al.
Publicado: (2019)

Anti-carbamylated protein antibodies in systemic sclerosis
por: Liem, Sophie I. E., et al.
Publicado: (2023)

The Effect of Ketoanalogues on Chronic Kidney Disease Deterioration: A Meta-Analysis
por: Li, Albert, et al.
Publicado: (2019)

The role of a low protein diet supplemented with ketoanalogues on kidney progression in pre-dialysis chronic kidney disease patients
por: Ariyanopparut, Saravanee, et al.
Publicado: (2023)

Phage-Display-Derived Peptide Specific to Carbamylated Protein
por: Ma, Yuhao, et al.
Publicado: (2021)

A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients
por: Kalantar-Zadeh, Kamyar
Publicado: (2012)

Ketoanalogues Supplemental Low Protein Diet Safely Decreases Short-Term Risk of Dialysis among CKD Stage 4 Patients
por: Yen, Chieh-Li, et al.
Publicado: (2022)

Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients
por: Lenglet, Aurelie, et al.
Publicado: (2023)

Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?
por: Gorisse, Laëtitia, et al.
Publicado: (2022)

Optimal predialysis care
por: Sijpkens, Yvo W. J., et al.
Publicado: (2008)

How important is dietary management in chronic kidney disease progression? A role for low protein diets
por: Ko, Gang-Jee, et al.
Publicado: (2021)

Kidney cachexia or protein‐energy wasting in chronic kidney disease: facts and numbers
por: Koppe, Laetitia, et al.
Publicado: (2019)

Long-Term Effects of Ketoanalogues on Mortality and Renal Outcomes in Advanced Chronic Kidney Disease Patients Receiving a Low-Protein Diet
por: Wang, Yi-Chun, et al.
Publicado: (2020)

Advanced Chronic Kidney Disease with Low and Very Low GFR: Can a Low-Protein Diet Supplemented with Ketoanalogues Delay Dialysis?
por: Yen, Chieh-Li, et al.
Publicado: (2020)

Carbamylated lipoproteins in diabetes
por: Denimal, Damien
Publicado: (2023)

Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease
por: Wu, Che-Hsiung, et al.
Publicado: (2017)

Ketoanalogue Supplementation in Patients with Non-Dialysis Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
por: Bellizzi, Vincenzo, et al.
Publicado: (2022)

Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis
por: Li, Liubing, et al.
Publicado: (2016)

Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor
por: Othman, Maizatul A., et al.
Publicado: (2017)

Protein Carbamylation: A Marker Reflecting Increased Age-Related Cell Oxidation
por: Carracedo, Julia, et al.
Publicado: (2018)

Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients
por: Vidal-Bralo, Laura, et al.
Publicado: (2017)

Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
por: Spinelli, Francesca Romana, et al.
Publicado: (2017)

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
por: Regueiro, Cristina, et al.
Publicado: (2017)

Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
por: Regueiro, Cristina, et al.
Publicado: (2021)

Patient education for phosphorus management in chronic kidney disease
por: Kalantar-Zadeh, Kamyar
Publicado: (2013)

The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis
por: Shi, Jing, et al.
Publicado: (2015)

Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies
por: Montes, Ariana, et al.
Publicado: (2016)

Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity
por: Bergum, Brith, et al.
Publicado: (2016)

Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis
por: Verheul, Marije K., et al.
Publicado: (2017)

Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association
por: Favoino, Elvira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_afvr03nf4bbmru6vf7e2dgmgsu